Similar results examining an increase in a progenitor exhausted PD1+ TCF1+ CD8+ population were reported by Miller and co-authors (2019) in patients with melanoma receiving anti CTLA-4 combined with anti-PD1 therapy. Here, CTLA4 is linked to melanoma.